Literature DB >> 35198

Clobazam: pharmacological and therapeutic profile.

G W Hanks.   

Abstract

1 Clobazam is a 1,5-benzodiazepine the pharmacological profile of which differs from that of the 1,4 benzodiazepines in that it displays a wide separation of psychosedative or 'tranquillizing' properties from impairment of motor coordination. This is associated with a relative lack of muscle relaxant activity. 2 In man it seems to be an effective anxiolytic agent when given in daily doses of 20-30 mg but produces minimal effects on psychomotor performance at these dose levels. 3 Clobazam has a long elimination half-life of about 18 h; the main metabolite is N-desmethylclobazam. Clobazam seems to share the good safety and tolerability characteristics of the 1,4 benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35198      PMCID: PMC1429523          DOI: 10.1111/j.1365-2125.1979.tb04685.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Kinetics and metabolism of clobazam in animals and man.

Authors:  M Volz; O Christ; H M Kellner; H Kuch; H W Fehlhaber; D Gantz; P Hajdu; F Cavagna
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Toxicology of clobazam.

Authors:  E Schütz
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Effect of the 1,5-benzodiazepines, clobazam and triflubazam, on sleep in man.

Authors:  A N Nicholson; B M Stone; C H Clarke
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

4.  Clobazam. A 1.5 benzodiazepine derivative: effects upon human psychomotor performance under different levels of task reinforcement.

Authors:  A C Parrott; I Hindmarch
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-04

5.  Neuropharmacological profile of clobazam, a new 1',5'-benzodiazepine.

Authors:  H J Gerhards
Journal:  Psychopharmacology (Berl)       Date:  1978-06-15       Impact factor: 4.530

6.  Clobazam versus diazepam--a double-blind study in anxiety neurosis.

Authors:  D R Doongaji; A Sheth; J S Apte; P D Lakdawala; C B Khare; S S Thatte
Journal:  J Clin Pharmacol       Date:  1978-07       Impact factor: 3.126

7.  Clobazam, a 1,5-benzodiazepine, and car-driving ability.

Authors:  I Hindmarch; G W Hanks; A J Hewett
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

8.  Immediate effects on human performance of a 1,5-genzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam.

Authors:  R G Borland; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

9.  Clobazam: chemical aspects of the 1,4 and 1,5-benzodiazepines.

Authors:  H Kuch
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

10.  Review of clinical studies on clobazam.

Authors:  D Koeppen
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

View more
  6 in total

1.  GABAergic Inhibition Gates Perceptual Awareness During Binocular Rivalry.

Authors:  Jeff Mentch; Alina Spiegel; Catherine Ricciardi; Caroline E Robertson
Journal:  J Neurosci       Date:  2019-08-26       Impact factor: 6.167

2.  An overview of third-generation antiseizure drugs: Clobazam, lacosamide, rufinamide, and vigabatrin.

Authors:  Marianna V Spanaki; Gregory L Barkley
Journal:  Neurol Clin Pract       Date:  2012-09

3.  Clobazam kinetics in the elderly.

Authors:  D J Greenblatt; M Divoll; S K Puri; I Ho; M A Zinny; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

4.  N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

Authors:  J R Haigh; T Pullar; J P Gent; C Dailley; M Feely
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 5.  Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

6.  Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

Authors:  Jennifer T Leahy; Catherine J Chu-Shore; Janet L Fisher
Journal:  Neuropsychiatr Dis Treat       Date:  2011-11-11       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.